US Medicare has little control over cancer drug costs,NEJM says
This article was originally published in Scrip
Executive Summary
US policymakers should amend laws that currently limit the Medicare programme's flexibility to rein in oncology drug costs and create a federal comparative effectiveness centre that could guide reimbursement decisions, an article in the New England Journal of Medicine says.